These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 30227362)

  • 21. Factors associated with initial or subsequent choice of biologic disease-modifying antirheumatic drugs for treatment of rheumatoid arthritis.
    Jin Y; Desai RJ; Liu J; Choi NK; Kim SC
    Arthritis Res Ther; 2017 Jul; 19(1):159. PubMed ID: 28679392
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Direct and indirect healthcare costs of rheumatoid arthritis patients in Turkey.
    Hamuryudan V; Direskeneli H; Ertenli I; Inanc M; Karaaslan Y; Oksel F; Ozbek S; Pay S; Terzioglu E; Balkan Tezer D; Hacibedel B; Akkoc N
    Clin Exp Rheumatol; 2016; 34(6):1033-1037. PubMed ID: 27749224
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Real-world utilization of DMARDs and biologics in rheumatoid arthritis: the RADIUS (Rheumatoid Arthritis Disease-Modifying Anti-Rheumatic Drug Intervention and Utilization Study) study.
    Gibofsky A; Palmer WR; Goldman JA; Lautzenheiser RL; Markenson JA; Weaver A; Schiff MH; Keystone EC; Paulus HE; Harrison MJ; Whitmore JB; Leff JA
    Curr Med Res Opin; 2006 Jan; 22(1):169-83. PubMed ID: 16393443
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Economic impact of expanded use of biologic therapy for the treatment of rheumatoid arthritis and Crohn's disease in Argentina, Brazil, Colombia, and Mexico.
    Tundia N; Kotze PG; Rojas Serrano J; Mendes de Abreu M; Skup M; Macaulay D; Signorovitch J; Chaves L; Chao J; Bao Y
    J Med Econ; 2016 Dec; 19(12):1187-1199. PubMed ID: 27376404
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prescription patterns and trends in anti-rheumatic drug use based on a large-scale claims database in Japan.
    Katada H; Yukawa N; Urushihara H; Tanaka S; Mimori T; Kawakami K
    Clin Rheumatol; 2015 May; 34(5):949-56. PubMed ID: 24420724
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Rheumatoid arthritis in Sweden. Drug prescriptions, costs, and adverse drug reactions.
    Blomqvist P; Feltelius N; Ekbom A; Klareskog L
    J Rheumatol; 2000 May; 27(5):1171-7. PubMed ID: 10813283
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cost per responder associated with biologic therapies for Crohn's disease, psoriasis, and rheumatoid arthritis.
    Liu Y; Wu EQ; Bensimon AG; Fan CP; Bao Y; Ganguli A; Yang M; Cifaldi M; Mulani P
    Adv Ther; 2012 Jul; 29(7):620-34. PubMed ID: 22843208
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Changes to the Australian Pharmaceutical Benefit Scheme restrictions for biological disease-modifying antirheumatic drugs have influenced the use of leflunomide.
    Hopkins AM; Vitry AI; O'Doherty CE; Proudman SM; Wiese MD
    Int J Rheum Dis; 2017 Nov; 20(11):1795-1797. PubMed ID: 26176865
    [No Abstract]   [Full Text] [Related]  

  • 29. Real-world cost-effectiveness of infliximab, etanercept and adalimumab in rheumatoid arthritis patients: results of the CREATE registry.
    Cárdenas M; de la Fuente S; Font P; Castro-Villegas M; Romero-Gómez M; Ruiz-Vílchez D; Calvo-Gutiérez J; Escudero-Contreras A; Casado M; Del Prado J; Collantes-Estévez E
    Rheumatol Int; 2016 Feb; 36(2):231-41. PubMed ID: 26494567
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cost-effectiveness of early treatment of ACPA-positive rheumatoid arthritis patients with abatacept.
    Neubauer AS; Minartz C; Herrmann KH; Baerwald CGO
    Clin Exp Rheumatol; 2018; 36(3):448-454. PubMed ID: 29303709
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Treatment patterns and annual biologic costs in US veterans with rheumatic conditions or psoriasis.
    Sauer BC; Teng CC; He T; Leng J; Lu CC; Walsh JA; Shah N; Harrison DJ; Tang DH; Cannon GW
    J Med Econ; 2016; 19(1):34-43. PubMed ID: 26337538
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Economic Burden and Treatment Patterns of Cycling between Conventional Synthetic Disease-modifying Antirheumatic Drugs Among Biologic-treated Patients with Rheumatoid Arthritis.
    Betts KA; Griffith J; Ganguli A; Li N; Douglas K; Wu EQ
    Clin Ther; 2016 May; 38(5):1205-16. PubMed ID: 27045991
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Use of a validated algorithm to estimate the annual cost of effective biologic treatment for rheumatoid arthritis.
    Curtis JR; Schabert VF; Yeaw J; Korn JR; Quach C; Harrison DJ; Yun H; Joseph GJ; Collier D
    J Med Econ; 2014 Aug; 17(8):555-66. PubMed ID: 24754646
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Control of rheumatoid arthritis with conventional disease-modifying antirheumatic drugs in a tertiary hospital in central South Africa.
    Carter RMN; Jansen van Rensburg BJ; Joubert G
    S Afr Med J; 2019 Dec; 110(1):27-31. PubMed ID: 31865939
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Financial cost of early rheumatoid arthritis in the first year of medical attention: three clinical scenarios in a third-tier university hospital in Colombia].
    Mora C; González A; Díaz J; Quintana G
    Biomedica; 2009 Mar; 29(1):43-50. PubMed ID: 19753838
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cost effectiveness of adding leflunomide to a 5-year strategy of conventional disease-modifying antirheumatic drugs in patients with rheumatoid arthritis.
    Maetzel A; Strand V; Tugwell P; Wells G; Bombardier C
    Arthritis Rheum; 2002 Dec; 47(6):655-61. PubMed ID: 12522841
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Modelling the cost effectiveness of TNF-alpha antagonists in the management of rheumatoid arthritis: results from the British Society for Rheumatology Biologics Registry.
    Brennan A; Bansback N; Nixon R; Madan J; Harrison M; Watson K; Symmons D
    Rheumatology (Oxford); 2007 Aug; 46(8):1345-54. PubMed ID: 17562686
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Costs in rheumatology: results and lessons learned from the 'Hannover Costing Study'.
    Hülsemann JL; Ruof J; Zeidler H; Mittendorf T
    Rheumatol Int; 2006 Jun; 26(8):704-11. PubMed ID: 16261384
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The use of adalimumab, etanercept, golimumab and infliximab in rheumatic pathologies: variation between label dosage and real-world use.
    Martinez-Cutillas J; Alerany-Pardo C; Borrás-Blasco J; Broto-Sumalla A; Burgos-SanJosé A; Climent-Bolta C; Escudero-Vilaplana V; Fernández-Fuente MA; Ferrit-Martin M; Gómez-Germá P; Martínez-Sesmero JM; Mayorga-Pérez J; Menchén-Viso B; Merino-Alonso J; Polache-Vengud J; Sánchez-Guerrero A
    Expert Rev Pharmacoecon Outcomes Res; 2015; 15(5):851-8. PubMed ID: 25972066
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cost-effectiveness of sequenced treatment of rheumatoid arthritis with targeted immune modulators.
    Jansen JP; Incerti D; Mutebi A; Peneva D; MacEwan JP; Stolshek B; Kaur P; Gharaibeh M; Strand V
    J Med Econ; 2017 Jul; 20(7):703-714. PubMed ID: 28294642
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.